XENE · ISSUER CIK 1582313
Xenon Pharmaceuticals Inc.
Between Jul 31, 2026 and Oct 28, 2026, 5 Xenon Pharmaceuticals Inc. insiders reported $1.7M of open-market purchases and $1.1M of sales on SEC Form 4. The largest buyer was Mortimer Ian (PRESIDENT & CEO, Director), with $1.1M.
↗5 insiders filed
Original Form 4 filings from Jul 31, 2026 to Oct 28, 2026. 1 of 2 sales were reported under a 10b5-1 plan.
$1.7MInsider buying
$1.1MInsider selling
+$615KNet open-market
Oct 16, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 16, 202620:22 | Oct 15, 2026 | XENE | Chief Financial Officer | M · Exercise | — | +7,500 | 22,500 | +50% | — | ||
| Oct 1, 202609:20 | Sep 30, 2026 | XENE | Chief Financial Officer | P · Buy | $37.32 | +15,000 | 15,000 | New | +$560K | -47.4% | -2.6% |
| Oct 1, 202609:19 | Sep 30, 2026 | XENE | PRESIDENT & CEO, Director | P · Buy | $37.38 | +30,000 | 49,923 | +151% | +$1.1M | -47.3% | -2.8% |
| Sep 3, 202620:26 | Sep 1, 2026 | XENE | Director | M · Exercise | $8.15 | +5,144 | 31,373 | +20% | $42K | ||
| Aug 31, 202621:59 | Aug 28, 2026 | XENE | Chief Medical Officer | S · Sell10b5-1 | $60.25 | −7,068 | 2 | -100% | −$426K | ||
| Aug 13, 202616:33 | Aug 11, 2026 | XENE | Director | S · Sell | $64.06 | −10,000 | 1,870 | -84% | −$641K |